McCullough Robertson’s Equity Capital Markets and Life Sciences team advised Imugene Limited (Imugene) in respect of raising up to $20 million through a two‑tranche placement and Share Purchase Plan, to support the continued development of azer‑cel and the generation of additional clinical data. In conjunction with the capital raising, we were engaged to assist with the entry into a new agreement with CVI Investments Inc. for convertible notes with a face value of $15.3 million.

Imugene is a clinical‑stage immuno‑oncology company developing innovative treatments that seek to activate the immune system to target and eliminate cancer. With an active clinical trial program, Imugene remains committed to delivering new therapeutic options to patients.

The McCullough Robertson team, led by Partner Reece Walker, has proudly worked with Imugene since 2013, and this continued engagement reflects the client’s ongoing trust in our expertise.